Question:
Request to suggest a frequency set for Pelizaeus-Merzbacher disease (PMD)
Answer:
Pelizaeus-Merzbacher Disease (PMD) is a rare genetic disorder that affects the central nervous system, specifically the white matter of the brain (myelin). It is a type of leukodystrophy, which is a group of disorders characterized by the abnormal development or destruction of the myelin sheath — the protective covering that insulates nerve fibers and allows for efficient signal transmission in the brain and spinal cord.
The Group in ETDFL which is equivalent in the treatment of Pelizaeus-Merzbacher Disease (PMD) especially in terms of underlying pathology and clinical behavior is: Leukodystrophy Spongiform
Leukodystrophy, Spongiform: 0.03, 0.26, 0.78, 7.5, 11.95, 55.54, 97.5, 515.7, 652.43, 758.78
Pelizaeus-Merzbacher Disease (PMD) is a hypomyelinating leukodystrophy, meaning the myelin never forms properly in the first place.
Spongiform leukodystrophies also involve abnormal formation or maintenance of myelin, rather than its destruction after normal formation. Both PMD and spongiform types show diffuse white matter abnormalities on brain imaging from infancy and are genetic in origin, often leading to early-onset neurodevelopmental symptoms like hypotonia, spasticity, and seizures.
Spongiform leukodystrophy is the closest to PMD in both mechanism (abnormal myelin formation) and clinical progression (early developmental delay, diffuse white matter changes, genetic origin). PMD is specifically due to PLP1 gene mutations, while spongiform types involve other gene mutations — but the overall pathophysiology and imaging findings are identical: The treatment therefore employs the equivalent frequency group Leukodystrophy Spongiform which has exact alignment to PMD
